Literature DB >> 16115590

Does visible atopic dermatitis affect quality of life more in women than in men?

Elisabeth A Holm1, Solveig Esmann, Gregor B E Jemec.   

Abstract

BACKGROUND: Studies have suggested that women overreport symptoms in nondermatologic disease. Gender-dependent differences in patients' perception of dermatologic disease are poorly described. The description of possible gender differences in morbidity in a skin disease with comparable prevalence in men and women may therefore provide relevant data.
OBJECTIVE: The goal of this study was to examine gender-dependent differences in the self-reported morbidity of patients with atopic dermatitis (AD).
METHODS: Questionnaires from members of the Atopisk Eksem Forening (Danish Association of Atopic Eczema) aged > or = 15 years were analyzed. Data were gathered regarding age, sex, disease duration and severity, and localization of AD, including the results of the Dermatology Life Quality Index (DLQI), a quality-of-life questionnaire designed for use in adults (ie, patients aged > or = 15 years).
RESULTS: Questionnaires from 112 patients were analyzed. The final study population comprised 88 females and 24 males; mean age was 35.3 years (range, 15-77 years). For women, a significant positive correlation was found between DLQI score and disease severity (P < 0.001) and also between DLQI score and visible regions affected by disease (P = 0.001); these correlations were not observed in men. For the total number of body regions affected, a significant correlation with severity was found for women (P = 0.001) but not for men. No significant differences between men and women were noted for age, disease duration, overall disease severity, or quality of life as assessed using the DLQI.
CONCLUSION: Self-reported morbidity is highly consistent among women with AD, but not so among men. Normally visible areas of AD appear to affect women significantly more than men.

Entities:  

Mesh:

Year:  2004        PMID: 16115590     DOI: 10.1016/s1550-8579(04)80017-2

Source DB:  PubMed          Journal:  Gend Med        ISSN: 1550-8579


  10 in total

1.  The global, regional, and national burden of atopic dermatitis in 195 countries and territories: An ecological study from the Global Burden of Disease Study 2017.

Authors:  Katelyn Urban; Sherman Chu; Rachel L Giesey; Sino Mehrmal; Prabhdeep Uppal; Natalie Nedley; Gregory R Delost
Journal:  JAAD Int       Date:  2020-11-30

2.  Measurement properties of three assessments of burden used in atopic dermatitis in adults.

Authors:  K R Patel; V Singam; P P Vakharia; R Chopra; R Sacotte; N Patel; S Immaneni; R Kantor; D Y Hsu; J I Silverberg
Journal:  Br J Dermatol       Date:  2018-11-12       Impact factor: 9.302

3.  The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study.

Authors:  Jaewon Lee; Jin Lim; Jong Seo Park; Miso Kim; Tae-Yong Kim; Tae Min Kim; Kyung-Hun Lee; Bhumsuk Keam; Sae-Won Han; Je-Ho Mun; Kwang Hyun Cho; Seong Jin Jo
Journal:  Cancer Res Treat       Date:  2017-12-14       Impact factor: 4.679

4.  Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults.

Authors:  J I Silverberg; J M Gelfand; D J Margolis; M Boguniewicz; L Fonacier; M H Grayson; P Y Ong; Z C Chiesa Fuxench; E L Simpson
Journal:  Br J Dermatol       Date:  2019-03-05       Impact factor: 9.302

5.  Erythema of Rosacea Affects Health-Related Quality of Life: Results of a Survey Conducted in Collaboration with the National Rosacea Society.

Authors:  Hilary E Baldwin; Julie Harper; Sarah Baradaran; Vaishali Patel
Journal:  Dermatol Ther (Heidelb)       Date:  2019-09-11

6.  The influence of animal species, gender and tissue on the structural, biophysical, biochemical and biological properties of collagen sponges.

Authors:  Anna Sorushanova; Ioannis Skoufos; Athina Tzora; Anne Maria Mullen; Dimitrios I Zeugolis
Journal:  J Mater Sci Mater Med       Date:  2021-01-21       Impact factor: 3.896

7.  Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.

Authors:  Andrew Alexis; Marjolein de Bruin-Weller; Stephan Weidinger; Weily Soong; Sebastien Barbarot; Ileana Ionita; Fan Zhang; Hernan Valdez; Claire Clibborn; Natalie Yin
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-17

8.  Quality of life in patients with skin diseases in central Saudi Arabia.

Authors:  Mostafa A Abolfotouh; Mohammad S Al-Khowailed; Wijdan E Suliman; Deema A Al-Turaif; Eman Al-Bluwi; Hassan S Al-Kahtani
Journal:  Int J Gen Med       Date:  2012-07-24

9.  Sex differences in itch perception and modulation by distraction--an FMRI pilot study in healthy volunteers.

Authors:  Astrid Stumpf; Markus Burgmer; Gudrun Schneider; Gereon Heuft; Martin Schmelz; Ngoc Quan Phan; Sonja Ständer; Bettina Pfleiderer
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

10.  Enhancement of Anti-Dermatitis Potential of Clobetasol Propionate by DHA [Docosahexaenoic Acid] Rich Algal Oil Nanoemulsion Gel.

Authors:  Mohammad Sarfaraz Alam; Mohammad Sajid Ali; Foziyah Zakir; Nawazish Alam; Mohammad Intakhab Alam; Faruque Ahmad; Masoom Raza Siddiqui; Mohammad Daud Ali; Mohammad Salahuddin Ansari; Sarfaraz Ahmad; Maksood Ali
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.